Monopar Therapeutics Inc.
MNPR
$43.15
$1.333.18%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 94.72% | -10.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 603.19% | -11.96% | |||
| Operating Income | -603.19% | 11.96% | |||
| Income Before Tax | -737.66% | 23.96% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -737.66% | 23.96% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -737.66% | 23.96% | |||
| EBIT | -603.19% | 11.96% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -501.46% | 24.34% | |||
| Normalized Basic EPS | -501.38% | 24.31% | |||
| EPS Diluted | -501.46% | 24.34% | |||
| Normalized Diluted EPS | -501.38% | 24.31% | |||
| Average Basic Shares Outstanding | 39.27% | 0.50% | |||
| Average Diluted Shares Outstanding | 39.27% | 0.50% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||